Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Net Cash Flow (2018 - 2025)

Inmune Bio's Net Cash Flow history spans 8 years, with the latest figure at -$5.6 million for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 300.71% year-over-year to -$5.6 million; the TTM value through Sep 2025 reached -$5.4 million, up 32.45%, while the annual FY2024 figure was -$15.2 million, 6.51% up from the prior year.
  • Net Cash Flow for Q3 2025 was -$5.6 million at Inmune Bio, down from $14.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $45.0 million in Q3 2021 and bottomed at -$13.1 million in Q4 2024.
  • The 5-year median for Net Cash Flow is -$3.4 million (2022), against an average of $1.3 million.
  • The largest annual shift saw Net Cash Flow skyrocketed 2338.7% in 2021 before it tumbled 774.32% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$9.8 million in 2021, then skyrocketed by 41.77% to -$5.7 million in 2022, then dropped by 3.62% to -$5.9 million in 2023, then crashed by 121.84% to -$13.1 million in 2024, then surged by 56.98% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Net Cash Flow are -$5.6 million (Q3 2025), $14.9 million (Q2 2025), and -$1.5 million (Q1 2025).